Upcoming Event: Pharma China Forum 2010 in Beijing
3/9/2010
Event: Pharma China Forum – The Dynamic Healthcare Market Environments in China
Organizer: Pharma China
Sponsors: RDPAC, ZS Associates and others TBD
Date: 1 PM to 5:00 PM, March 26, 2010
Venue: ChangAn Club, Beijing, China
Contact: David Xue, Chief Representative, Pharma China
Tel: +86 13911325130
Event Highlights
- Contemporary trends & issues in Chinese pharma in 2009 and early 2010
- Healthcare reform and drug policy impacts on the Chinese pharma sector
- Changing dynamics in Chinese pharmaceutical regulation
- Latest trends in China's pharmaceutical IP and legal environments
- Interactive discussion and brainstorming with its panel of top experts
Introduction
Despite uncertainties in the global pharmaceutical arena, output value of the Chinese pharmaceutical industry surged another 17.8% in the first half of 2009. Both the output value and sales value for all sub-sectors of the industry rose at double digit rates.
On top of the high output value and sales growth, the industry's total profits and total net profits jumped 15% and 22% respectively in the first seven months. Profits of large companies enjoyed the highest growth in the period.
The ongoing healthcare reform, under which rural and community healthcare will be heavily invested, is beginning to change the landscape of the Chinese pharmaceutical sector with many new policies, in particular the country's essential drug, reimbursement and pricing policies, falling into place. Although implementation of China's healthcare reform has just begun, its impacts are already felt strongly in some areas.
Meanwhile, China's drug regulation regime has continued to evolve in search of better solutions to secure drug safety and efficacy while fostering innovation and supporting industry development.
Following China's WTO entry in 2002, the country has been moving its intellectual property rights (IPR) regime closer to those found in many more developed nations. Despite the substantial progress made in this area, a number of issues continue to remain. Besides, strengthened regulations and enforcements in this area have led to an increase in the number of IPR infringement cases being brought before the courts or taken up through China's administrative procedures.
As China's legal system evolves and becomes sophisticated, the Chinese population has become increasingly aware of their patient rights in the healthcare process which also has resulted in a growing number of lawsuits related to the quality of medical services and drug products. Consequently, pharmaceutical companies are facing a more challenging legal environment in the country than just a few years ago.
This Pharma China Forum event in English is to be hosted by Pharma China and sponsored by RDPAC and others (TBD).
The event seeks to improve understanding of new healthcare policies and drug regulations, draw attention to the remaining pharmaceutical IP issues and alert on the changing legal environment for drug companies.
Four leading experts will share their knowledge, insights and expertise in contemporary market trends, healthcare reform and policy direction, drug regulation and IP/legal issues. The presentation will be followed by an interactive panel discussion with speakers and other experts.
Agenda
|
|
Simple registration, refreshments, networking |
|
1:00 – 1:05 |
Opening and introduction of Pharma China and sponsors |
|
1:05 – 1:45 |
James Shen, Publisher and Chief Editor, Pharma China
Review of Recent Trends and Developments in the Chinese Pharma Industry
- Market overview - 2009 and early 2010
- Latest trends of the pharmaceutical industry and market
- Latest developments in drug regulation and healthcare reform |
|
1:45 – 2:30 |
John Woo, President Greater China, IMS Health
Outlook and Therapeutic Trends of the Chinese Pharmaceutical Market |
|
2:30 – 3:15 |
Vivian Chen, Director of Healthcare Economics, RDPAC
The Dynamics of China’s Healthcare Reform and Its Future Policy Directions |
|
3:15 – 3:30 |
Break, refreshments and networking |
|
3:30 – 4:10 |
Songjun Luo and Chris Arzt, Chief Representatives, ZS Associates China
Impacts of Healthcare Reform on Pharmaceutical Business Model in China |
|
4:10 – 4:40 |
Rising Product Liability Challenges that Pharmas Face in China
- Increasing monetary claims in product liability cases
- The phenomenon and how to address it
- Impact of the new PRC Tort Liability Law |
|
4:40 – 5:00 |
Panel Discussion/Q&As with
- James Shen, Publisher and Chief Editor, Pharma China
- Three speakers |
|
After 5:00 |
Voluntary after-event Q&As, discussions and networking |
Fee (covering attendance and refreshments)
CNY 800 – Pharma China subscribers and employees of RDPAC members
CNY 1,200 - Non-subscribers of Pharma China
Sponsorship opportunities
Please contact us about sponsorship packages for refreshments and after-event cocktail.
Registration
Spaces are limited to 100 participants and priority is given to Pharma China subscribers and employees of RDPAC member companies. Please contact:
David Xue
Tel: +86 10 8530-0937 Cell: +86 13911325130